Multicentre Phase I Study with an 8-Dose Regimen of Single Agent Anti-CD20 Monoclonal Antibody LFB-R603 in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). By admin / 12/13/2011
A Phase I study of LFB-R603, a Novel Anti-CD20 Antibody, in Patients with Relapsed Chronic Lymphocytic Leukemia. By admin / 12/07/2010
